Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Obiltoxaximab

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Increasing bacterial resistance to antibiotics is a worldwide ongoing issue. Urgent need for new antibacterial agents has… Expand
  • figure 1
  • table 1
2018
2018
Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective… Expand
Review
2017
Review
2017
Objective: To review the safety and efficacy of obiltoxaximab, a monoclonal antibody indicated for the treatment of Bacillus… Expand
  • table 1
  • table 2
  • table 3
2017
2017
Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax under the… Expand
2017
2017
ABSTRACT The recommended management of inhalational anthrax, a high-priority bioterrorist threat, includes antibiotics and… Expand
Review
2016
Review
2016
Obiltoxaximab (Anthim®, ETI-204) is a monoclonal antibody that is being developed by Elusys Therapeutics and the US Department of… Expand
2016
2016
ABSTRACT The Centers for Disease Control and Prevention recommend adjunctive antitoxins when systemic anthrax is suspected… Expand
2016
2016
ABSTRACT Inhalational anthrax has high mortality even with antibiotic treatment, and antitoxins are now recommended as an adjunct… Expand
2016
2016
PURPOSE This report describes the safety, immunogenicity, and pharmacokinetic results of obiltoxaximab treatment in healthy… Expand
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
2016
2016
A new agent used to treat and prevent inhalational anthrax has received FDA approval. Obiltoxaximab, marketed as Anthim, is… Expand